Endocytic defects caused by elimination of the type I myosins (myo3Δ myo5Δ) or WASp (las17Δ) are suppressed by clc1-Δ19-76. (A) Growth with myo3Δ myo5Δ: wild type (SL1462), clc1-Δ19-76 (SL6044), myo3Δ myo5Δ (SL6561), myo3Δ myo5Δ clc1-Δ19-76 (SL6576), myo5Δ (SL6580), and myo5Δ clc1-Δ19-76 (SL6579) were fivefold serially diluted, plated on YEPD, and grown at 30 or 37°C for 60 h. (B) Growth of las17Δ (SL6602) and las17Δ clc1-Δ19-76 (SL6603) as in A. (C) Representative kymographs of Sla1-GFP/Abp1-RFP patches in wild type (SL5311), myo5Δ (SL6579), myo5Δ clc1-Δ19-76 (SL6554), myo3Δ myo5Δ (SL6562), and myo3Δ myo5Δ clc1-Δ19-76 (SL6575). (D) Representative kymographs of Sla2-GFP/Abp1-RFP patches in wild type (SL5311), myo5Δ (SL6569), myo5Δ clc1-Δ19-76 (SL6572), myo5Δ myo3Δ (SL6566), and myo3Δ myo5Δ clc1-Δ19-76 (SL6568). (E) Representative kymographs of Sla1-GFP/Abp1-RFP patches in las17Δ (SL6596) and las17Δ clc1-Δ19-76 (SL6597). (F) Representative kymographs of Sla2-GFP/Abp1-RFP patches in las17Δ (SL6598) and las17Δ clc1-Δ19-76 (SL6600). (G) Fluorescence lifetimes of Sla2-GFP, Sla1-GFP, and Abp1-RFP in strains shown in C–F. Data are reported as average ± SD (n ≥ 50). †p ≤ 0.0009 vs. wild type; *p ≤ 0.004 vs. wild type; #p ≤ 0.0001 vs. myo3Δ myo5Δ; °p ≤ 0.0003 vs. myo5Δ; ‡p ≤ 0.0001 vs. las17Δ.